Usefulness of Iron Deficiency Correction in Management of Patients with Heart Failure (From the RAID-HF Registry)

• Published in: The American journal of cardiology Vol. 118; no. 12; pp. 1875 - 1880
• Main Authors: Wienbergen, Harm, MD, Pfister, Otmar, MD, Hochadel, Matthias, PhD, Michel, Stephan, Bruder, Oliver, MD, Remppis, Björn Andrew, MD, Maeder, Micha, MD, Strasser, Ruth, MD, von Scheidt, Wolfgang, MD, Pauschinger, Matthias, MD, Senges, Jochen, MD, Hambrecht, Rainer, MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 15-12-2016; Elsevier Limited
• Subjects: Age; Aged; Aged, 80 and over; Anemia; Anemia, Iron-Deficiency - complications; Anemia, Iron-Deficiency - diagnosis; Anemia, Iron-Deficiency - drug therapy; Anemia, Iron-Deficiency - epidemiology; C-Reactive Protein - metabolism; Cardiomyopathy; Cardiovascular; Cohort Studies; Disease Management; Female; Ferric Compounds - therapeutic use; Germany - epidemiology; Health risk assessment; Heart failure; Heart Failure - complications; Heart Failure - therapy; Humans; Iron - therapeutic use; Logistic Models; Logistics; Male; Maltose - analogs & derivatives; Maltose - therapeutic use; Middle Aged; Multivariate Analysis; Natriuretic Peptide, Brain - blood; Odds Ratio; Peptide Fragments - blood; Peptides; Prevalence; Quality of life; Registries; Software; Standard deviation; Switzerland - epidemiology; Trace Elements - therapeutic use; Treatment Outcome; Germany; iron therapy; heart failure; iron deficiency; anemia
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2016.08.081

Abstract Iron deficiency (ID) has been identified as an important comorbidity in patients with heart failure (HF). Intravenous iron therapy reduced symptoms and rehospitalisations of iron-deficient HF-patients in randomised trials. The present multicenter study investigated the “real-world” management of iron status in patients with HF. Consecutive patients with HF and ejection fraction < 40% were recruited and analyzed from 12/2010 to 10/2015 by 11 centres in Germany and Switzerland. Out of 1484 patients with HF, iron status was determined in only 923 patients (62.2%), despite participation of the centres in a registry focusing on ID and despite guideline recommendation to determine iron status. In patients with determined iron status, a prevalence of 54.7% (505 patients) for ID was observed. Iron therapy was performed in only 8.5% of the iron-deficient HF-patients; 2.6% were treated with intravenous iron therapy. The patients with iron therapy were characterised by a high rate of symptomatic HF and anemia. In conclusion despite strong evidence of beneficial effects of iron therapy on symptoms and rehospitalisations, diagnostic and therapeutic efforts on ID in HF are low in the actual clinical practice, and the awareness to diagnose and treat ID in HF should be strongly enforced.